AI Value Creator

AI Value Creator for Evidence-Based Value Messaging

Transform scientific evidence into clear, consistent and evidence-based value messages using AI built for pharma and medtech teams.

The gap between scientific evidence and value messaging

Scientific evidence is widely available, but transforming it into clear, consistent value messages remains slow and manual in life sciences. Evidence is reviewed in silos, insights are fragmented, and value narratives are repeatedly recreated, causing most scientific insights to lose strategic impact before they ever become usable value messages.

Unlinked claims illustration
Unlinked Claims

Value messages are not connected to their sources

Value messages are created in documents or slides without a direct link to the supporting evidence. Citations are added later β€” or lost β€” increasing rework and compliance risk.

Manual workflows illustration
Manual Workflows

Move between tools to create value

Teams jump between alerts, PDFs, documents and slides to extract claims and citations. Evidence is scattered across tools, slowing down interpretation and making value creation manual and fragile.

Manual citation search illustration
Manual Citation Search

Finding the right citation takes too long

Teams re-read full papers to locate the sentence or endpoint that supports a claim. This manual citation finding process is slow, error-prone, and impossible to scale as evidence grows.

From scientific evidence to decision-ready value messaging

The AI Value Creator transforms scientific evidence into structured, ready-to-use value messages aligned with your strategy. By analyzing curated, verified sources, it generates clear, evidence-based narratives and automatically stores each message with full context, references, and traceability β€” allowing teams to move from raw evidence to consistent value messaging faster and with less effort.

app.centivence.com/value-creator
Messages in this Story
Manage and organize your value messages
Showing 19 of 19 messages
PATIENT OUTCOMES PAYERS

Lebrikizumab combined with TCS was found to provide comparable relief from itching, a significant symptom burden in atopic dermatitis, relative to dupilumab plus TCS. At week 16, the odds of achieving a β‰₯ 4-point improvement in the Pruritus Numeric Rating Scale score (PNRS β‰₯ 4) were OR 0.48 (95% CI 0.17–1.37). This indicates that both treatments are effective in addressing one of the most disabling symptoms of AD, supporting patient-centric value arguments around symptom control and quality of life satisfaction.

EXCERPT
At week 16, lebrikizumab plus TCS had comparable odds to dupilumab plus TCS of achieving PNRS β‰₯ 4 (OR 0.48, 95% CI 0.17–1.37).
SOURCE
Chovatiya R. Short-Term Efficacy of Lebrikizumab Versus Dupilumab... https://doi.org/...
ECONOMIC VALUE PAYERS

Lebrikizumab demonstrates a significant cost-effectiveness advantage over tralokinumab in treating moderate-to-severe atopic dermatitis. The cost per responder at week 16 for lebrikizumab was $67,932 for achieving EASI-75 compared to $130,655 for tralokinumab. Additionally, the cost per responder at week 52 was $109,412 compared to $176,622 for tralokinumab. These lower costs per responder indicate that lebrikizumab offers a more economically efficient treatment option for payers while effectively addressing the clinical needs of patients.

PATIENT OUTCOMES PHYSICIANS

Pediatric atopic dermatitis (AD) poses significant challenges, impacting both children and their families, with lebrikizumab being among the recommended systemic therapies for the management of pediatric AD, highlighting lebrikizumab's role in improving patient outcomes when used with concomitant topical therapies.

Generate messages from evidence

Select the publications that matter and let the AI build structured value messages in seconds β€” each grounded in the evidence you trust.

Full citation traceability

Every message is linked to its source paper, the exact excerpt it draws from, and a direct reference β€” ready for payer meetings, dossiers, or MSL conversations.

Tailored by stakeholder

Generate different message versions for Payers, Physicians, or Patients from the same evidence base β€” each framed to what that audience needs to hear.

Flagged when evidence changes

When new publications are detected, the system flags which messages may need updating β€” so your value narratives are always consistent with the latest data.

How our AI Value Creator works?

Step 1

Select the scientific evidence

Choose the scientific articles you want to transform, either from your existing baskets or by uploading new papers into the platform.

Step 2

Define the strategic context

Specify the product, comparators, stakeholders, and the objective of the value messages you want to generate. This ensures messages are aligned with your strategy from the start.

Step 3

Generate value messages

The AI Value Creator analyzes the selected evidence and transforms it into structured, evidence-based value messages tailored to your defined context.

Step 4

Save and reuse instantly

Generated messages are automatically saved in the platform, ready to be reviewed, reused, and managed across teams.

An AI Value Creator built for regulated life sciences

The Centivence AI Value Creator transforms scientific evidence into accurate, traceable value messages within a controlled environment. By generating messages exclusively from curated evidence and saving them with full context and references, it enables consistent, reliable value creation at scale.

A closed evidence environment you can trust

Centivence operates within a structured scientific workspace where publications are curated, context is preserved, and evidence is continuously traceable. The AI can only reason over the evidence you select, ensuring that every message remains scientifically grounded and aligned with your strategy.

Secure environment illustration

Evidence and claims managed in one platform

Centivence centralizes all evidence, value messages, and claims into a single structured workspace. Teams can easily manage, update, and reuse approved messaging without duplicating work or losing scientific context β€” maintaining consistency and control as strategies evolve.

Strategy centralized illustration

Stop managing evidence.
Start using it.

See how Centivence gives your Medical Affairs, Marketing, and Market Access teams a single system to find, organise, and act on scientific evidence.

Book a demo